+1 858-523-8231
Login | Register
menu
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
366017-09-6,MFCD09954135
Catalog No.:AA0078QG

366017-09-6 | Mubritinib

Pack Size
Purity
Availability
Price(USD)
Quantity
  
5mg
≥98%
in stock  
$56.00   $39.00
- +
10mg
≥98%
in stock  
$106.00   $74.00
- +
50mg
≥98%
in stock  
$383.00   $268.00
- +
100mg
≥98%
in stock  
$710.00   $497.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA0078QG
Chemical Name:
Mubritinib
CAS Number:
366017-09-6
Molecular Formula:
C25H23F3N4O2
Molecular Weight:
468.4709
MDL Number:
MFCD09954135
SMILES:
FC(c1ccc(cc1)/C=C/c1occ(n1)COc1ccc(cc1)CCCCn1nncc1)(F)F
Properties
Computed Properties
 
Complexity:
620  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0  
Defined Bond Stereocenter Count:
1  
Formal Charge:
0  
Heavy Atom Count:
34  
Hydrogen Bond Acceptor Count:
8  
Hydrogen Bond Donor Count:
0  
Isotope Atom Count:
0  
Rotatable Bond Count:
10  
Undefined Atom Stereocenter Count:
0  
Undefined Bond Stereocenter Count:
0  
XLogP3:
5.4  

Downstream Synthesis Route

[1]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-US2003/69419,2003,A1

[2]Wang,Rong;Cui,Menghan;Yang,Qing;Kuang,Chunxiang[Synthesis,2021,vol.53,#5,p.978-982]

[3]Allen,TimothyE.H.;Chung,Injae;Fischer,Peter;Hardy,Rachel;Harvey,RobertF.;Hirst,Judy;Kellam,Barrie;Macfarlane,Marion;Mistry,Sarah;Pryde,KennethR.;Serreli,Riccardo;Stephenson,ZoëA.;Stoneley,Mark;Willis,AnneE.[eLife,2020,vol.9]

[4]CurrentPatentAssignee:UNIVERSITYOFMONTREAL-WO2019/84662,2019,A1Locationinpatent:Page/Pagecolumn93

[5]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-US2002/173526,2002,A1

[6]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-US2004/138160,2004,A1

366016-82-2   
CASUnavailable 
  1643-19-2    115093-99-7    534-07-6    366017-09-6   
CASUnavailable 

[1]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-US2003/69419,2003,A1

[1]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-US2003/69419,2003,A1

[1]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-US2003/69419,2003,A1

Literature

Title: A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.

Journal: The Biochemical journal 20130415

Title: Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.

Journal: Nature biotechnology 20111101

Title: Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.

Journal: International journal of urology : official journal of the Japanese Urological Association 20060501

Title: Nagasawa J, et al. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int J Urol. 2006 May;13(5):587-92.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
Submit
SDS
Related Products of 366017-09-6
Building Blocks
More >
Tags:366017-09-6 Molecular Formula|366017-09-6 MDL|366017-09-6 SMILES|366017-09-6 Mubritinib
Catalog No.: AA0078QG
366017-09-6,MFCD09954135
366017-09-6 | Mubritinib
Pack Size： 5mg
Purity： ≥98%
in stock
$56.00 $39.00
Pack Size： 10mg
Purity： ≥98%
in stock
$106.00 $74.00
Pack Size： 50mg
Purity： ≥98%
in stock
$383.00 $268.00
Pack Size： 100mg
Purity： ≥98%
in stock
$710.00 $497.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA0078QG
Chemical Name: Mubritinib
CAS Number: 366017-09-6
Molecular Formula: C25H23F3N4O2
Molecular Weight: 468.4709
MDL Number: MFCD09954135
SMILES: FC(c1ccc(cc1)/C=C/c1occ(n1)COc1ccc(cc1)CCCCn1nncc1)(F)F
Properties
Complexity: 620  
Covalently-Bonded Unit Count: 1  
Defined Atom Stereocenter Count: 0  
Defined Bond Stereocenter Count: 1  
Formal Charge: 0  
Heavy Atom Count: 34  
Hydrogen Bond Acceptor Count: 8  
Hydrogen Bond Donor Count: 0  
Isotope Atom Count: 0  
Rotatable Bond Count: 10  
Undefined Atom Stereocenter Count: 0  
Undefined Bond Stereocenter Count: 0  
XLogP3: 5.4  
Downstream Synthesis Route
366016-82-2    366016-66-2    366017-09-6 

[1]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-US2003/69419,2003,A1

[2]Wang,Rong;Cui,Menghan;Yang,Qing;Kuang,Chunxiang[Synthesis,2021,vol.53,#5,p.978-982]

[3]Allen,TimothyE.H.;Chung,Injae;Fischer,Peter;Hardy,Rachel;Harvey,RobertF.;Hirst,Judy;Kellam,Barrie;Macfarlane,Marion;Mistry,Sarah;Pryde,KennethR.;Serreli,Riccardo;Stephenson,ZoëA.;Stoneley,Mark;Willis,AnneE.[eLife,2020,vol.9]

[4]CurrentPatentAssignee:UNIVERSITYOFMONTREAL-WO2019/84662,2019,A1Locationinpatent:Page/Pagecolumn93

[5]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-US2002/173526,2002,A1

[6]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-US2004/138160,2004,A1

366016-82-2   
CASUnavailable 
  1643-19-2    115093-99-7    534-07-6    366017-09-6   
CASUnavailable 

[1]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-US2003/69419,2003,A1

109-99-9    366016-82-2    391202-31-6    1643-19-2    124-63-0    366017-09-6   
CASUnavailable 

[1]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-US2003/69419,2003,A1

366016-82-2    391202-31-6    1643-19-2    124-63-0    366017-09-6   
CASUnavailable 

[1]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-US2003/69419,2003,A1

Literature fold

Title: A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.

Journal: The Biochemical journal20130415

Title: Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.

Journal: Nature biotechnology20111101

Title: Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.

Journal: International journal of urology : official journal of the Japanese Urological Association20060501

Title: Nagasawa J, et al. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int J Urol. 2006 May;13(5):587-92.

Related Products of of 366017-09-6
Building Blocks More >
375345-95-2
375345-95-2
Ly451395
AA0079FO | MFCD18251566
36415-21-1
36415-21-1
2-(Furfurylthio)ethylamine
AA0079ZX | MFCD01075029
111439-76-0
111439-76-0
Silane,dimethoxy(1-methylethyl)(2-methylpropyl)-
AA007AHV | MFCD00239345
1070879-58-1
1070879-58-1
4-Bromo-2-methyl-8-trifluoromethylquinoline
AA007B3G | MFCD11505142
108857-24-5
108857-24-5
2-Amino-5-iodo-3-methylbenzoic acid
AA007BM0 | MFCD09029816
17288-54-9
17288-54-9
5-(Benzyloxy)-1H-pyrrolo[2,3-c]pyridine
AA007C8B | MFCD09038914
3364-80-5
3364-80-5
Thiazole-4-carboxaldehyde
AA007CQH | MFCD00626896
171879-75-7
171879-75-7
2-[4-(Methylsulfanyl)phenyl]benzonitrile
AA007DBC | MFCD05981388
34581-23-2
34581-23-2
1-(3-Methylbutyl)piperazine
AA007E02 | MFCD08442096
104162-47-2
104162-47-2
1-Propanamine, N,N-dimethyl-2,3-bis[(9Z)-9-octadecenyloxy]-
AA007EJQ | MFCD22200991
Submit
© 2017 AA BLOCKS, INC. All rights reserved.